Epitope Analysis of Antibodies in Japanese to Human Cytomegalovirus Phosphoprotein 150 with Synthetic Peptides

2002 ◽  
Vol 66 (11) ◽  
pp. 2402-2405 ◽  
Author(s):  
Isao TAKAHASHI ◽  
Sayoko SUGIURA ◽  
Hirotoshi OHTA ◽  
Kazuo OZAWA ◽  
Tadashi KAMIYA
Keyword(s):  
Human Cytomegalovirus ◽  
Synthetic Peptides ◽  
Epitope Analysis

Epitope analysis of human cytomegalovirus glycoprotein complexes using murine monoclonal antibodies

Virology ◽  
1988 ◽  
Vol 164 (2) ◽  
pp. 362-372 ◽  
Author(s):  
Nancy O. Lussenhop ◽  
Ron Goertz ◽  
Mel Wabuke-Bunoti ◽  
Richard Gehrz ◽  
Bruce Kari
Keyword(s):  
Monoclonal Antibodies ◽  
Human Cytomegalovirus ◽  
Epitope Analysis ◽  
Murine Monoclonal Antibodies

scholarly journals Antineutrophil cytoplasmic antibodies to proteinase 3 in Wegener's granulomatosis: Epitope analysis using synthetic peptides

2001 ◽  
Vol 59 (1) ◽  
pp. 147-159 ◽  
Author(s):  
Ymke M. Van Der Geld ◽  
Arjan Simpelaar ◽  
Ruurd Van Der Zee ◽  
Jan Willem Cohen Tervaert ◽  
Coen A. Stegeman ◽  
...  
Keyword(s):  
Synthetic Peptides ◽  
Wegener’S Granulomatosis ◽  
Wegener's Granulomatosis ◽  
Antineutrophil Cytoplasmic Antibodies ◽  
Proteinase 3 ◽  
Epitope Analysis

Epitope analysis using kinetic measurements of antibody binding to synthetic peptides presenting single amino acid substitutions

1993 ◽  
Vol 6 (2) ◽  
pp. 71-79 ◽  
Author(s):  
Gabrielle Zeder-Lutz ◽  
Danièle Altschuh ◽  
Sandra Denery-Papini ◽  
Jean Paul Briand ◽  
Marc H. V. Van Regenmortel ◽  
...  
Keyword(s):  
Amino Acid ◽  
Synthetic Peptides ◽  
Antibody Binding ◽  
Single Amino Acid ◽  
Amino Acid Substitutions ◽  
Kinetic Measurements ◽  
Epitope Analysis

scholarly journals Epitope Analysis of Staphylococcal Enterotoxin A Using Different Synthetic Peptides.

1998 ◽  
Vol 60 (9) ◽  
pp. 993-996 ◽  
Author(s):  
Dong-Liang HU ◽  
Ayako IMAI ◽  
Katsuhiko ONO ◽  
Sanae SASAKI ◽  
Akio NAKANE ◽  
...  
Keyword(s):  
Synthetic Peptides ◽  
Staphylococcal Enterotoxin ◽  
Staphylococcal Enterotoxin A ◽  
Epitope Analysis

scholarly journals Mapping of serologically relevant regions of human cytomegalovirus phosphoprotein pp150 using synthetic peptides

1991 ◽  
Vol 72 (6) ◽  
pp. 1409-1413 ◽  
Author(s):  
J. Novak ◽  
P. Sova ◽  
V. Krchnak ◽  
E. Hamsikova ◽  
H. Zavadova ◽  
...  
Keyword(s):  
Human Cytomegalovirus ◽  
Synthetic Peptides

Ristocetin and Botrocetin Involve Two Distinct Domains of von Willebrand Factor for Binding to Platelet Membrane Glycoprotein lb

1990 ◽  
Vol 64 (02) ◽  
pp. 326-332 ◽  
Author(s):  
J P Girma ◽  
Y Takahashi ◽  
A Yoshioka ◽  
J Diaz ◽  
D Meyer
Keyword(s):  
Von Willebrand Factor ◽  
Synthetic Peptides ◽  
Competitive Inhibition ◽  
Final Concentration ◽  
Binding Domain ◽  
Platelet Membrane ◽  
Platelet Glycoprotein ◽  
Membrane Glycoprotein ◽  
Von Willebrand ◽  
Willebrand Factor

SummaryWe have evidence that ristocetin and botrocetin mediate binding of von Willebrand Factor (vWF) to platelet glycoprotein lb (GPIb) through two distinct domains on the vWF molecule. This was established by using monoclonal antibodies (MAbs) to vWF and synthetic peptides derived from the sequence of vWF. MAb 322 and MAb NMC/vW 4 both recognize native vWF as well as fragments containing the GPIb-binding domain of vWF, obtained with the following enzymes: trypsin (116 kDa), V-8 pro tease (Spill, 320 kDa) and V-8 protease plus subtilisin (33-28 kDa). Nevertheless, the lack of reciprocal displacement between the two MAbs in experiments of competitive inhibition for binding to vWF demonstrate that their respective epitopes are separate. Both MAbs inhibit 125I-vWF binding to platelet membrane GPIb and vWF-dependent platelet agglutination induced by ristocetin. However, only MAb NMC/vW4 inhibits these functions in the presence of botrocetin and when ristocetin-induced platelet agglutination is inhibited by MAb 322, botrocetin is still able to restore the agglutination. The involvement of two distinct domains of vWF for binding to GPIb in the presence of ristocetin or botrocetin was confirmed in experiments of binding of 125I-vWF to platelets using as competitor synthetic peptides corresponding to the GPIb binding domain of vWF (Cys 474 to Pro 488 and Ser 692 to Pro 708). At a final concentration of 2.5 mM both peptides inhibit more than 90% of the binding of vWF to ristocetin-treated platelets but are unable to modify this binding in the presence of botrocetin. In conclusion our data suggest that botrocetin and ristocetin involve distinct sites on vWF for binding to GPIb.

Sign in / Sign up

Export Citation Format

Share Document